- |||||||||| morphine sulphate / Generic mfg.
Symptomatic Catheter Tip Granuloma in a Patient With High Dose Intrathecal Morphine Therapy: To Explant or Not to Explant (126A) - Jun 25, 2024 - Abstract #ASA2024ASA_3143;
Only three drugs (morphine, baclofen, and ziconotide) are approved by the US Food and Drug Administration (FDA) for use in intrathecal pain pump, but several drugs are used off-label, such as hydromorphone, fentanyl, sufentanyl, ketamine, clonidine, and bupivacaine...This case discusses the use of the combination of long- and short-acting oral opioids in the process of rapid weaning off intrathecal opioids in a patient with an IDDS.CASE HISTORYThe patient is a 66-year-old female with a past medical history significant for pulmonary embolism, deep venous thrombosis (on Xarelto), bipolar disorder, asthma, chronic obstructive pulmonary disease, and chronic low back pain...Her pain is well controlled with oxycontin 30 mg bid and oxycodone 15 mg tid...Will you agree?9)Why did this patient develop granuloma at the tip of intrathecal catheter in the first place? Does it relate to the content of drug or it can happen to anyone with intrathecal drug delivery?10)Your new pain fellow asked if there is anything you can do prevent formation of granuloma in other patients.1
- |||||||||| morphine sulphate / Generic mfg.
Symptomatic Catheter Tip Granuloma in a Patient With High Dose Intrathecal Morphine Therapy: To Explant or Not to Explant (126A) - Jun 25, 2024 - Abstract #ASA2024ASA_3028;
Only three drugs (morphine, baclofen, and ziconotide) are approved by the US Food and Drug Administration (FDA) for use in intrathecal pain pump, but several drugs are used off-label, such as hydromorphone, fentanyl, sufentanyl, ketamine, clonidine, and bupivacaine...This case discusses the use of the combination of long- and short-acting oral opioids in the process of rapid weaning off intrathecal opioids in a patient with an IDDS.CASE HISTORYThe patient is a 66-year-old female with a past medical history significant for pulmonary embolism, deep venous thrombosis (on Xarelto), bipolar disorder, asthma, chronic obstructive pulmonary disease, and chronic low back pain...Her pain is well controlled with oxycontin 30 mg bid and oxycodone 15 mg tid...Will you agree?9)Why did this patient develop granuloma at the tip of intrathecal catheter in the first place? Does it relate to the content of drug or it can happen to anyone with intrathecal drug delivery?10)Your new pain fellow asked if there is anything you can do prevent formation of granuloma in other patients.1
- |||||||||| fentanyl citrate / Generic mfg., oxycodone controlled release / Generic mfg.
Journal: The effect of opioid use on traffic fatalities. (Pubmed Central) - Apr 29, 2024
The effect is mainly concentrated in fatal crashes with drug involvement of drivers ages between 25 and 44. Our results highlight additional long-term detrimental consequences of the introduction and marketing of OxyContin.
- |||||||||| OxiFast (oxycodone immediate release) / Purdue, Shionogi, Mundipharma
Enrollment open, Trial initiation date, Surgery: 5x-Multiplier vs 3-Tier Model for Discharge Opioid Prescriptions After Intra-abdominal Cancer Surgery: A Randomized Clinical Trial (clinicaltrials.gov) - Mar 29, 2024
P2, N=150, Recruiting,
Compared with oral oxycontin tablet, the use of PCSA with hydromorphone achieved a shorter titration duration for patients with cancer pain (p<0.001), without significantly increasing adverse events (p=0.32). Not yet recruiting --> Recruiting | Initiation date: Jun 2024 --> Mar 2024
- |||||||||| fentanyl citrate / Generic mfg.
A Rare Case of Alcoholic hepatitis/ Fentanyl-induced Renal TMA () - Mar 23, 2024 - Abstract #NKFSCM2024NKF_SCM_574;
INTRODUCTION: Thrombotic Microangiopathy (TMA) represents a pathologic diagnosis in which abnormalities in the microvasculature lead to thrombosis that can affect multiple organs including the kidneys. It is important to recognize these substances, including opioid derived or synthetic formulations, as possible triggers for TMA.
- |||||||||| fentanyl citrate / Generic mfg., oxycodone/acetaminophen / Generic mfg., oxycodone controlled release / Generic mfg.
Outcomes of an Opioid Education and Naloxone Distribution Program in Juvenile Hall in San Diego (Convention Center Exhibit Hall) - Mar 16, 2024 - Abstract #PAS2024PAS_2755;
Of all 49 individuals who participated, there was a statistically significant increase in the number who, after training, correctly identified heroin, oxycontin and fentanyl as opioids (p < 0.010), correctly identified trouble breathing as a sign of opioid overdose (p < 0.004), wanted to help someone who overdosed (p < 0.017), felt they would know how to help someone who overdosed (p < 0.001), and reported not needing additional training in order to feel confident helping someone who overdosed (p < 0.007). All participants successfully completed simulation of nasal injection.
- |||||||||| pethidine / Samaritan Pharma
Patterns of Outpatient Opioid Prescriptions in Yinzhou, China: A Decade-Long Study (2011-2021) () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_238;
This is the first report detailing outpatient opioid prescription duration, daily OME, and initial user patterns in China, revealing lower opioid use rates, average durations, and doses compared to North America, UK, and Australia, suggesting relatively safe opioid use in China. However, the presence of high-risk prescriptions highlights the need for enhanced monitoring of adverse events and pain assessment in outpatient settings.
- |||||||||| oxycodone controlled release / Generic mfg.
Journal: Inside "Operation Change Agent": Mallinckrodt's Plan for Capturing the Opioid Market. (Pubmed Central) - Feb 7, 2024
This research on internal corporate strategy adds to growing challenges to industry claims that opioid sales teams simply educated providers and helped fill existing demand for their products. Moreover, this research has important implications for regulatory policy and consumer protections that can better protect health in the face of competitive market forces.
- |||||||||| Palexia RP (tapentadol extended release) / Assertio, J&J, Grunenthal, Collegium Pharma
Journal: Comparison of the effects of OPRM1 A118G polymorphism using different opioids: A prospective study. (Pubmed Central) - Jan 15, 2024
Moreover, this research has important implications for regulatory policy and consumer protections that can better protect health in the face of competitive market forces. Tapentadol and methadone may be more suitable than hydromorphone, oxycodone, and fentanyl for G-allele carriers due to their dual mechanism of action and low susceptibility to OPRM1 A118G polymorphism.
- |||||||||| Enrollment open: No-PAIN: NSAID Use After Robotic Partial Nephrectomy (clinicaltrials.gov) - Sep 6, 2023
P2, N=110, Recruiting,
Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Jun 2024 --> Jun 2025 Not yet recruiting --> Recruiting
- |||||||||| Decadron (dexamethasone) / Merck (MSD), Ozurdex (dexamethasone intravitreal implant) / AbbVie, Exparel (bupivacaine liposome injectable suspension) / Pacira
Trial completion, Trial completion date: Efficacy of Opioid-limiting Pain Management Protocol in Men Undergoing Urethroplasty (clinicaltrials.gov) - Aug 1, 2023
P4, N=60, Completed,
It also might be used for appropriate education and dissemination of information to persons engaged in drug use content on Twitter. Recruiting --> Completed | Trial completion date: Oct 2023 --> Jun 2023
- |||||||||| Prialt (ziconotide) / Jazz
Lost In Conversion: Intrathecal Opioids To Equivalent Oral Opioids In Chronic Pain Patients (South: Hall D-7) - Jul 20, 2023 - Abstract #ASA2023ASA_2332;
Only three drugs (morphine, baclofen, and ziconotide) are approved by the US Food and Drug Administration (FDA) for use in intrathecal pain pump, but several drugs are used off-label, such as hydromorphone, fentanyl, sufentanyl, ketamine, clonidine, and bupivacaine...This case discusses the use of the combination of long- and short-acting oral opioids in the process of rapid weaning off intrathecal opioids in a patient with an IDDS.CASE HISTORYThe patient is a 66-year-old female with a past medical history significant for pulmonary embolism, deep venous thrombosis (on Xarelto), bipolar disorder, asthma, chronic obstructive pulmonary disease, and chronic low back pain...Her pain is well controlled with oxycontin 30 mg bid and oxycodone 15 mg tid...Will you agree?9)Why did this patient develop granuloma at the tip of intrathecal catheter in the first place? Does it relate to the content of drug or it can happen to anyone with intrathecal drug delivery?10)Your new pain fellow asked if there is anything you can do prevent formation of granuloma in other patients.
- |||||||||| Prialt (ziconotide) / Jazz
Lost In Conversion: Intrathecal Opioids To Equivalent Oral Opioids In Chronic Pain Patients (South: Hall D-7) - Jul 20, 2023 - Abstract #ASA2023ASA_368;
Only three drugs (morphine, baclofen, and ziconotide) are approved by the US Food and Drug Administration (FDA) for use in intrathecal pain pump, but several drugs are used off-label, such as hydromorphone, fentanyl, sufentanyl, ketamine, clonidine, and bupivacaine...This case discusses the use of the combination of long- and short-acting oral opioids in the process of rapid weaning off intrathecal opioids in a patient with an IDDS.CASE HISTORYThe patient is a 66-year-old female with a past medical history significant for pulmonary embolism, deep venous thrombosis (on Xarelto), bipolar disorder, asthma, chronic obstructive pulmonary disease, and chronic low back pain...Her pain is well controlled with oxycontin 30 mg bid and oxycodone 15 mg tid...Will you agree?9)Why did this patient develop granuloma at the tip of intrathecal catheter in the first place? Does it relate to the content of drug or it can happen to anyone with intrathecal drug delivery?10)Your new pain fellow asked if there is anything you can do prevent formation of granuloma in other patients.
- |||||||||| morphine sulphate / Generic mfg., oxycodone controlled release / Generic mfg.
OPIOID USE REDUCTION BY OXYCODONE MORPHINE FORMULARY SWITCH () - May 12, 2023 - Abstract #EHA2023EHA_3151;
Switching from oxycodone to morphine as the preferred oral opioid for hemato-oncology patients with pain reduces both the oral opioid use during admission and the number of patients with an oral opioid prescription at discharge. Since the reduction in opioid use resulted in no differences in overall pain control, the oxycodone morphine switch warrants further implementation.Figure 1: number of clinical prescriptions for opioids at the hematology ward Drug interaction, Side effects, Quality of life
- |||||||||| Decadron (dexamethasone) / Merck (MSD), Ozurdex (dexamethasone intravitreal implant) / AbbVie, Exparel (bupivacaine liposome injectable suspension) / Pacira
Trial primary completion date: Efficacy of Opioid-limiting Pain Management Protocol in Men Undergoing Urethroplasty (clinicaltrials.gov) - Mar 20, 2023
P4, N=60, Recruiting,
Patients in the non-opioid placebo group spent more time mobilized the first week after surgery than those in the tapentadol ER and the oxycodone CR groups, while the number of steps was not different between the groups. Trial primary completion date: Oct 2022 --> Apr 2023
- |||||||||| Rapinyl (fentanyl) / Kyowa Kirin, Orexo, Zydus Cadila, OxiFast (oxycodone immediate release) / Purdue, Shionogi, Mundipharma
Journal: Medical opioid disposal in Fukuoka and Kumamoto cities. (Pubmed Central) - Mar 9, 2023
Trial primary completion date: Oct 2022 --> Apr 2023 In Fukuoka city, the most disposed opioid was 20 mg Oxycontin, worth approximately 940,000
- |||||||||| oxycodone controlled release / Generic mfg.
Journal: A Qualitative Study of the Pain Experience of Black Individuals With Cancer Taking Long-Acting Opioids. (Pubmed Central) - Feb 5, 2023
Among individuals assessed for substance use, a differential decline in non-oral abuse of brand ER oxycodone was observed since introduction of ORF. Clinicians should partner with patients with cancer, especially people of color, who may experience intersecting stigmas related to their cancer pain and opioid use, to best provide an individualized and culturally sensitive pain treatment plan.
- |||||||||| grapiprant (RQ-00000007) / AskAt, Ikena Oncology, Maruishi Pharma
Trial completion date, Trial initiation date, Trial primary completion date, Combination therapy: 3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain (clinicaltrials.gov) - Jan 4, 2023
P2a/2b, N=177, Not yet recruiting,
Clinicians should partner with patients with cancer, especially people of color, who may experience intersecting stigmas related to their cancer pain and opioid use, to best provide an individualized and culturally sensitive pain treatment plan. Trial completion date: Sep 2023 --> Sep 2024 | Initiation date: Sep 2022 --> Sep 2023 | Trial primary completion date: Jun 2023 --> Jun 2024
|
